Physician profile
Charles Mayron
NPI 1831119932
$2,137.79
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.03 · 2020: $43.79 · 2021: $108 · 2022: $208 · 2023: $722 · 2024: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $1,194.03 | 2023-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $246.58 | 2019-2024 | Eylea Hd, Eylea |
| Genentech USA, INC. | $219.63 | 2021-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $107.95 | 2023-2024 | Syfovre |
| Bausch & Lomb Americas INC. | $58.93 | 2024 | Xipere, Retisert, Visudyne |
| Abbvie INC. | $50.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $39.25 | 2021-2022 | |
| Astellas Pharma US INC | $34.32 | 2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $32.54 | 2023 | Bromsite, Xelpros, Cequa |
| Halozyme INC | $32.18 | 2021-2022 | |
| Genentech, INC. | $26.21 | 2024 | Vabysmo, Susvimo |
| Biotissue Holdings INC. | $22.95 | 2021 | |
| Alcon Vision LLC | $22.67 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $17.72 | 2023 | Iyuzeh |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mayron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.